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CObjective: To evaluate the cost-effectiveness of a socioculturally
adapted collaborative depression care program among low-income
Hispanics with diabetes. Research design and methods: A random-
zed controlled trial of 387 patients with diabetes (96.5% Hispanic) with
linically significant depression followed over 18months evaluated the
ost-effectiveness of the Multifaceted Diabetes and Depression Pro-
ram aimed at increasing patient exposure to evidence-based depres-
ion psychotherapy and/or pharmacotherapy in two public safety net
linics. Patient medical care costs and utilization were captured from
os Angeles County Department of Health Services claims records. Pa-
ient-reported outcomes included Short-Form Health Survey-12 and
atient Health Questionnaire-9-calculated depression-free days.
esults: Intervention patients had significantly greater Short-Form
ealth Survey-12 utility improvement from baseline compared with
ontrols over the 18-month evaluation period (4.8%; P  0.001) and a O
o rep
er fo
.
al So
oi:10.1016/j.jval.2011.09.008orresponding significant improvement in depression-free days (43.0;
 0.001). Medical cost differences were not statistically significant in
rdinary least squares and log-transformed cost regressions. The av-
rage costs of theMultifaceted Diabetes and Depression Program study
ntervention were $515 per patient. The program’s cost-effectiveness
veraged $4053 per quality-adjusted life-year per MDDP recipient and
as more than 90% likely to fall below $12,000 per quality-adjusted
ife-year. Conclusions: Socioculturally adapted collaborative depres-
ion care improved utility and quality of life in predominantly low-
ncome Hispanic patients with diabetes and was highly cost-effective.
eywords: depression, diabetes-related complications, direct care
ealth costs, cost-utility analysis, randomized clinical trial.
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Diabetes is the fifth leading cause of death amongHispanics and is
twice as prevalent in this population as in non-Hispanicwhites [1],
with Mexican Americans being 1.9 times more likely to have dia-
betes compared with non-Hispanic white adults of similar age [2].
The comorbidity of diabetes and depression is estimated to be
around 25% in the elderly Mexican American population [3] and as
high as 33% in Hispanic primary care samples [4,5]. Hispanics also
have greater risk of cardiovascular illness and functional disabil-
ity, and difficulty with diabetes management can contribute to
depression [4,6]. Compared with non-Hispanic whites, Hispanics
are less likely to receive guideline-congruent depression care even
after controlling for clinical and economic factors [7], more likely
to be served by physicians who fail to detect amental health prob-
lem when one exists [8,9], and at higher risk to discontinue anti-
depressant use during the first 30 days of treatment [10,11].
A randomized clinical trial implemented a health services ef-
fectiveness collaborative care model—the Multifaceted Diabetes
and Depression Program (MDDP)—aimed at increasing exposure
Conflicts of interest: The authors have no conflicts of interest t
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098-3015/$36.00 – see front matter Copyright © 2012, Internation
ublished by Elsevier Inc.of low-income, predominantly Hispanic diabetes patientswith co-
morbid depression to evidence-based depression psychotherapy
and/or pharmacotherapy to examine both the quality of depres-
sion care and outcomes comparedwith enhanced usual care (EUC)
[12]. As shown by Ell and colleagues [12], MDDP intervention pa-
tients had significantly greater depression improvement com-
pared with usual care patients. As Ell et al. reported, although
there was no statistically significant improvement in glycemic
control, there were significant improvements over 18 months in
reported diabetes symptoms, anxiety, Short-Form Health Sur-
vey-12 (SF-12) emotional, physical, and pain-related functioning,
Sheehan disability, financial situation, and number of social stres-
sors (P 0.04 for disability and SF-12 physical and P 0.001 for all
others).
Prior studies of predominantly non-Hispanic whites have
found similar depression care interventions to be highly cost-ef-
fective in older adults withmultiple chronicmedical illnesses [13],
older adults with diabetes comorbidity [14], and adults with dia-
betes comorbidity visiting primary care clinics of a large health
maintenance organization [15]. To our knowledge this is the first
ort.
r Health Policy and Economics, University of Southern California,
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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250 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 2 4 9 – 2 5 4research to evaluate the cost-effectiveness of a randomized con-
trolled trial depression intervention targeted at low-income His-
panic patients with diabetes comorbidity.
Methods
As described by Ell and colleagues [12], the randomized controlled
trial, approved by the University of Southern California Institu-
tional Review Board, was conducted in Los Angeles County public
community clinics. Trained bilingual study recruiters identified
diabetes patients from medical charts. Study-eligible patients
were 18 years or older, reported at least one of two cardinal de-
pression symptoms (items 1 or 2 of the Patient Health Question-
naire-9 [PHQ-9] survey) more than half the days in a 2-week
prestudy period, and also scored 10 on the PHQ-9, indicating a
high likelihood of clinically significant depression. Patients meet-
ing study criteriawere randomized to either EUC or theMDDP. Key
elements in the MDDP are based on evidence-based depression
practice guidelines for primary care and are responsive to known
barriers to treatment among patients in public safety net clinics.
The structured stepped care algorithm 12-month intervention in-
cluded 1) Problem-solving therapy provided by bilingual graduate
social work diabetes depression clinical specialists (DDCS) and/or
antidepressant medications prescribed by the treating primary
care provider (PCP); 2) DDCS monthly telephone follow-up symp-
tommonitoring, treatment maintenance, and relapse prevention;
and 3) care and service system navigation by the DDCS and an
assistant patient navigator. A psychiatrist and PI (Ell) provided
weekly telephone DDCS supervision and, if requested, the psychi-
atrist provided PCP antidepressant medication telephone consul-
tation.
EUC patients received standard clinic care and in additionwere
given patient- and family-focused depression educational pam-
phlets (Spanish or English) and a community, financial, social ser-
vices, transportation, and child care resource list. EUC PCPs were
informed of patient depression diagnoses and their study partici-
pation and could prescribe antidepressants or refer patients to
communitymental health care. Patients could also independently
seek mental health treatment.
Data collection
The complete set of data collection instruments is described in
detail elsewhere [12]. Patients were surveyed at baseline, and out-
omes were reported at 6-month intervals thereafter (out to 24
onths). Consistent with the prior assessment of study outcomes
12], we evaluated the cost and cost-effectiveness outcomes
ithin the 18-month follow-up evaluation period. Cost and cost-
ffectiveness results measured out to 24 months were similar.
Depression-free days (DFDs)were calculated from the PHQ-9. A
PHQ-9 score of 5 meant that the patient has one full DFD, and a
PHQ-9 score of 14 meant 0 DFDs. Scores between 5 and 14 re-
flected linearly interpolated (0–1) depression scores between re-
mission andmajor depression [16]. The PHQ-9was used because it
provides both a dichotomous diagnosis of major depression and a
continuous severity score and has been found to have high sensi-
tivity and specificity for a diagnosis of major depressive disorder
(MDD) based on structured psychiatric interview [17,18]. Health-
related quality of life (QoL) was assessed by using the Medical
Outcomes Study Short-Form Health Survey (SF-12) Physical Com-
ponent Summary and Mental Component Summary fitted to the
Brazier and Roberts SF-6D utility scale [19]. These utility scores
were used to estimate quality-adjusted life-years (QALYs) gained
during the evaluation period relative to baseline.
Medical care costs and utilization were obtained from Los An-
geles County Department of Health Service electronicmedical ser-
vices records for all study patients, based on Medicare Interna-tional Classification of Diseases-9, Diagnosis-Related Groups,
National Drug Code, and Current Procedures Terminology-4cod-
ing. Because county payments are confidential and also so as to
make the cost analysis generalizable beyond southern California,
we used 2009Medicare prices tomeasuremedical service costs per
unit. Medicare prices (payment amounts allowed by Medicare)
were attached to these medical services based on the RBRVS EZ-
Fees software program that creates and analyzes physician pay-
ments by usingMedicare’s Resource Based Relative Value Scale for
all services except pharmaceuticals [20]. Because the Medicare
outpatient drug program (Medicare Part D) was not implemented
until after the study was initiated, drug prices were obtained from
the 2009 Federal Supply Schedule price list [21]. Because the same
2009 prices were assigned to all medical services, regardless of
time period, medical cost inflation was not relevant to the cost
estimates.
Intervention costs were measured as actual budget-based cost
(not charges) for all DDCS and patient navigator services, using
actual salary plus a 32% fringe benefit. Resulting unit costs were
$71 per patient visit (90 minutes), $35 per DDCS telephone fol-
low-up (45 minutes), and $10 for each patient navigation call
(10–15 minutes). Estimates included record keeping time. Addi-
tional costs included $10 for relaxation videotape, $136 per patient
for DDCS communicationwith PCP, and $21 per patient for clinical
supervision.
Statistical methods
The key outcomes of interest for the cost-effectiveness analysis
weremedical and intervention costs, DFDs, and SF-12 utilities.We
conducted the primary cost-effectiveness analysis in terms of cost
per QALY from a payer perspective, with additional consideration
of the overall impacts on medical costs, QoL, and DFDs.
Intent-to-treat analysis was conducted to evaluate all inter-
vention effects. Differences-in-differences regression models
were estimated to evaluate systematic cost and utilization differ-
ences between EUC and MDDP at 6-, 12- and 18-month follow-up
[22,23]. The differences-in-differences regression analysismethod
is a powerful method for adjusting for any individual-specific un-
observable factors that are time-invariant and account for varia-
tion in the outcomes.
This is demonstrated in the following equation specification.
Suppose that we are interested in the regression specification for
an outcome Oit, where i is the subscript for individual i and t is the
subscript for time period t (Oi0 represents outcomes measured at
the preintervention baseline for individual i). Suppose we have a
(1 J) vector of J observable exogenous characteristicsXit, with the
jth characteristic Xijt for individual i at time t. Suppose there is an
additional (1 K) vector of K time-invariant unobservable individ-
ual-level exogenous characteristics Ii (e.g., underlying health, per-
onal attitudes and/or behaviors, personality traits, aptitudes, and
ackground) with the kth unobservable characteristic Iik. Let eit
represent the residual random error for each individual i at each
time point t. Then, we can write the panel data regression specifi-
cation for Oit as
Oi00Xi0li ei0 t 0 (1)
Oit0Xi0liXit Treatment1 Time2 Time
2 eit
t 6, 12, 18 months (2)
here  is the treatment effect parameter and 1 and 2 capture a
(quadratic) time trend.
We can combine Equations 1 and 2 into the differencing esti-
mation equation:
Oit
∗ OitOi0Xit Treatment1 Time2 Time2 eit∗t 6, 12, 18 months
(3)
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251V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 2 4 9 – 2 5 4where e*it (eitei0). Using this differencing specification in Equa-
ion 3, the 0 and  parameters for all baseline exogenous charac-
eristics (both observed and unobserved), which are unnecessary
or estimating treatment effects, are netted out of the final estima-
ion equation.
Because the cost distributionwas skewed, in addition to a stan-
ard cost regression specification we also used a log-normal cost
istribution estimation equation. Tests of heteroskedasticity
cross treatment groups were not significant, implying that Duan
mearing estimates for retransformation bias were not necessary
24]. A Park Test for alternative generalized linear model specifi-
ations failed to reject the log-normal error specification for the
ost regression [25].
As previously shown by Ell and colleagues [12], therewas a lack
f balance in treatment assignment between the EUC and MDDP
reatment groups, with many baseline characteristics being sta-
istically significantly different across treatment assignment de-
pite randomization. In order to adjust for any potential observ-
ble variable confounding between treatment assignment and
ost or other outcome variables we present both ordinary least
quareand propensity score–adjusted regression estimates [26].
he propensity score used was the predicted probability of treat-
ent assignment from a logistic regression of actual treatment
ssignment on all available observed patient baseline character-
stics. These baseline values of exogenous factors that were signif-
Table 2 – Medical cost regression estimates.
Independent variables
Medic
PS*
(Constant) 395.99 (0.755)
Age 26.62 (0.089)
Males 70.12 (0.838)
Number of diabetes complications 52.90 (0.670)
Number of economic stressors 81.66 (0.201)
Chronic disease score 18.01 (0.688)
Time 187.08 (0.296)
Time squared 6.76 (0.361)
MDDP treatment 32.85 (0.903)
Propensity score 1693.64 (0.010)
MDDP, Multifaceted Diabetes and Depression Program; OLS, ordinary
* Propensity score estimated by using predicted logistic probability
Table 1 – Medical cost category average differences from b
Mean 6-month unadjuste
cost differences from
baseline ($)
EUC MDD
Medications 179.89 57.
Laboratory 51.86 54.
Emergency department 8.46 7.
Outpatient 65.60 12.
Inpatient 35.15 273.
Miscellaneous/other* 171.43 49.
Total 82.31 315.
EUC, enhanced usual care; MDDP, Multifaceted Diabetes and Depress
* Cost results are averaged across the three 6- to 18-month study pe
† Miscellaneous/other includes home care, durable medical equipmebaseline predictors (see text).cantly associated with treatment assignment included age, gen-
er, Latino ethnicity, foreign born, residing in the country more
han 10 years, married, primarily Spanish speaking, less than high
chool education, unemployed, number of economic stressors,
istory of major depressive disorder, dysthymia, chronic pain,
aking medications for pain, chronic disease score, number of di-
betes complications, and treatment clinic site. Since treatment
ssignment in the trial was not balanced on observable baseline
actors, it is appropriate to use a regression method that captures
nd adjusts for variation in baseline observable factors.
Results
Table 1 provides the average 6- to 18-month difference-from-base-
line cost comparisons between the control andMDDP intervention
patients relative to the 6-month baseline period prior to study
implementation for totalmedical costs alongwith the cost subcat-
egories of medications, laboratory tests, emergency department,
outpatient, inpatient, and miscellaneous/other. While there is a
trend for many of the cost category savings from baseline to be
greater in the MDDP intervention group, this result was statisti-
cally significant only for the medication cost category (P  0.007;
95% CI  $64.44 to $410.39) and was offset by higher miscella-
neous/other costs in the intervention group. Antidepressant med-
Estimated coefficient (P value)
sts Natural log of medical costs
OLS PS* OLS
140.91 (0.912) 0.363 (0.387) 0.358 (0.391)
22.82 (0.144) 0.015 (0.003) 0.015 (0.003)
30.10 (0.930) 0.044 (0.700) 0.045 (0.689)
101.54 (0.409) 0.081 (0.046) 0.082 (0.042)
58.44 (0.356) 0.008 (0.701) 0.008 (0.710)
29.92 (0.505) 0.018 (0.236) 0.018 (0.239)
189.61 (0.291) 0.082 (0.166) 0.082 (0.166)
6.83 (0.358) 0.003 (0.276) 0.003 (0.277)
291.02 (0.246) 0.026 (0.772) 0.030 (0.718)
0.027 (0.903)
t squares; PS, propensity score.
atment assignment as a correction for observed confounding using
ne*.
95% confidence interval for
EUC-MDDP difference-in-
difference ($)
P value
Lower Upper
64.44 410.39 0.007
22.87 28.22 0.837
35.55 3.06 0.099
184.26 27.96 0.149
78.96 695.87 0.119
395.22 47.13 0.013
194.92 660.88 0.286
rogram.
There were no significant within-period differences.
nd additional medical costs not otherwise specified.al co
leas
of treaseli
d
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252 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 2 4 9 – 2 5 4ication use was significantly higher in the MDDP intervention
group.
As shown in Table 2, looking at differences-in-differences from
baseline, none of the medical cost regressions showed a signifi-
cant change in costs, whether propensity score adjusted or not
andwhether log-transformed or not. TheMDDP intervention vari-
able was statistically insignificant in all cases (Table 2).
As shown in Table 3, the MDDP intervention was associated
with a significant increase in utility, as measured on the predicted
SF-12 utility scale (0.048; P  0.001; 95% CI  0.028–0.068) in the
ropensity score regression specification. This utility gain trans-
ated into an average 0.13 increased QALYs for the MDDP group
elative to the control group over the 18-month evaluation period
net of the baseline difference-in-difference values). The DFDs re-
ressions showed a highly significant improvement in DFDs for
he treatment group (Table 3).
The averageMDDP intervention cost per patient was $515 (95%
I $469–$561) (Table 4). Because the cost regressions showed no
ignificant differences in medical treatment costs, we computed
he MDDP program cost-effectiveness under an assumption of no
edical cost savings from the MDDP intervention and including
he additional study intervention costs per MDDP patient as cap-
ured in the patient study logs. As shown in Table 4, under this
ssumption the average incremental cost per QALY for the MDDP
ntervention, (CostMDDP - CostEUC)/(QALYMDDP - QALYEUC), was
4053.
As shown in Figure 1, to capture sampling uncertainty in our
ost/QALY estimates using the nonparametric bootstrap method
27], we generated a cost-effectiveness acceptability curve from
he individual-specific pairs of costs and QALYs for the study sub-
ects, again under the assumption that there were nomedical cost
Table 3 – Utility and depression-free days regression estim
Independent variables
SF-12 u
PS*
(Constant) 0.710 (0.000)
Age 0.001 (0.068)
Males 0.002 (0.888)
Number of diabetes complications 0.019 (0.000)
Number ofeconomic stressors 0.012 (0.000)
Chronic disease score 0.000 (0.902)
Time 0.003 (0.603)
Time squared 0.000 (0.700)
MDDP treatment 0.048 (0.000)
Propensity score 0.033 (0.157)
MDDP, Multifaceted Diabetes and Depression Program; OLS, ordinary
* Propensity score regression estimated by using predicted logistic pr
ing based on baseline predictors (see text).
Table 4 – Base case cost/QALY estimates*.
Control MDDP
intervention
Incremental
cost
effectiveness
QALYs gained 0.92 1.05 0.13
MDDP costs $0.00 $515 $ 515
Cost/QALY $4053
MDDP,Multifaceted Diabetes andDepression Program; QALY, qual-
ity-adjusted life-year.
* All estimates computed relative to baseline.avings from the MDDP intervention. This cost-effectiveness ac-
eptability curve showed that there was more than a 50% proba-
ility that theMDDP interventionwas cost-effective at a threshold
illingness-to-pay of $5000 per QALY and more than a 90% prob-
bility that the MDDP intervention was cost-effective at a willing-
ess-to-pay threshold of $12,000 per QALY.
Comment
To our knowledge this is the first economic evaluation of a ran-
domized controlled trial of collaborative depression care for pre-
dominantly low-income Hispanic patients with diabetes in public
safety net clinics. The findings suggest that a collaborative depres-
sion care model, socioculturally adapted for low-income patients,
resulted in significant improvements in QoL compared with EUC.
The intervention was cost-effective, with a conservatively esti-
mated cost per QALY below $5000 andmore than 90% likely to fall
below $12,000 per QALY. These cost-effectiveness results demon-
strated that the MDDP intervention was highly cost-effective un-
der conventional cost-effectiveness value guidelines reported in
the literature [28–32]. The results were well within the highly fa-
.
Estimated coefficient (P value)
Depression-free days
OLS PS* OLS
0.715 (0.000) 12.62 (0.688) 22.89 (0.469)
0.001 (0.089) 0.64 (0.102) 0.48 (0.217)
0.004 (0.762) 5.89 (0.489) 9.93 (0.245)
0.018 (0.000) 16.92 (0.000) 18.87 (0.000)
0.012 (0.000) 12.57 (0.000) 13.51 (0.000)
0.000 (0.788) 0.11 (0.921) 0.37 (0.741)
0.003 (0.597) 19.25 (0.000) 19.15 (0.000)
0.000 (0.696) 0.03 (0.870) 0.02 (0.883)
0.053 (0.000) 42.98 (0.000) 32.57 (0.000)
68.26 (0.000)
t squares; PS, propensity score; SF-12, Short-Form Health Survey-12.
ility of treatment assignment as a correction for observed confound-
Fig. 1 – Cost-effectiveness acceptability curve. QALY,ates
tility
leas
obabquality-adjusted life-year.
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253V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 2 4 9 – 2 5 4vorable range compared with widely-accepted medical interven-
tions (www.CEAregistry.org) and well within cost-effectiveness
value-of-life thresholds of $100,000 to $150,000 per QALY reported
in the economic literature for U.S. estimates [28–32].
Improving depression symptoms in patients with diabetes in
rior collaborative care studies has been shown to be associated
ith a high probability of achieving savings in total ambulatory
edical costs in comparisons with usual primary care [33]. In that
tudy, the higher costs associated with providing enhanced men-
al health care were offset by greater savings in medical costs [33].
lack and colleagues [34] found in a large longitudinal study of an
aging Hispanic population in the southwestern United States that
depression markedly increases the risk of macro- and microvas-
cular complications, incident physical disability, and mortality in
patients with diabetes. Several other studies in diverse popula-
tions have also confirmed that comorbid depression increased risk
of microvascular and macrovascular complications and mortality
in patients with diabetes [13,35].
Our cost regression models did not find that the MDDP inter-
vention was associated with significant medical cost savings, and
so we did not incorporate medical cost savings into our base case
cost-effectiveness results. Thus, while theMDDP interventionwas
found to be highly cost-effective, further studies are needed to
ascertain whether improving outcomes of depression in patients
with diabetes would decrease medical costs in this population.
Longer term studieswould also be needed to establish the impacts
of such interventions on changes in patient disability, disease
complications, and overall survival.
Limitations
Certain study limitations are discussed in the prior publication [5].
The main study limitation relevant to our cost-effectiveness re-
sults was the statistically significant imbalance of the MDDP and
EUC study groups at baseline randomization. We thoroughly in-
vestigated all potential causes for this randomization imbalance,
and even though it is highly unlikely to have happened by chance,
we have no explanation for why so many baseline observable
characteristics were significantly different between the MDDP in-
tervention and control groups.
This randomization imbalance necessitated exploration of al-
ternative propensity score–adjusted regression estimation meth-
ods to control for potential treatment assignment bias. The pro-
pensity score that we used for treatment assignment deals with
the appropriate source of observable confounding.While our find-
ings, however, were robust to alternative regression specifications
based on available study variables, we cannot claim the same de-
gree of robustness for these results aswe could have if the baseline
randomization had succeeded in balancing the study groups on all
observable confounders.
Finally, the estimated MDDP intervention costs did not explic-
itly include facility, space, or other administrative overhead ex-
penses. However, given that the mean wage for mental health
social workers in California inMay 2009was $22.28/h (http://www.
bls.gov/oes/current/oes_ca.htm#21-0000), these intervention cost
estimates would conservatively include an approximate 40%mar-
gin for such overhead costs.
Conclusion
Socioculturally and organizationally adapted collaborative care is
highly cost-effective in improving QoL outcomes in a low-income,
predominantly Hispanic population in safety net clinics.Acknowledgments
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